Emily Purcell, MD, Colin Ligon, MD, MHS, & Chris T. Derk, MD, MS
Related Articles
Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do
Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure
New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
Hydroxychloroquine (HCQ) therapy may effectively manage systemic lupus erythematosus (SLE) in many patients, but that doesn’t mean patients will take it as often as they should. In fact, results from a recently published study found that about half of SLE patients were not adherent.1 The study was led by Lucy H. Liu, MD, MPH, a…
New Study Probes Hydroxychloroquine Adherence During Pregnancy
Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…
Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…